However, the data is so compelling that the company could receive FDA approval and have this drug on the market by next year. This would greatly accelerate revenue forecasts, and the interest generated in the stock would be substantial. The prospects for Imclone over the long term looks good, but in the short run, once the excitement has died, there could be a temporary dip in Imclone Therapeutics' share price, because I'm betting that once the meeting's is over, the Street is going to lock in their profits. It's going to be monkey see, monkey do, in other words, sell and then buy back the shares. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company.
Additional information is available upon request.
Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments.